Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER
Autore:
ARMAND JP; DUCREUX M; MAHJOUBI M; ABIGERGES D; BUGAT R; CHABOT G; HERAIT P; DEFORNI M; ROUGIER P;
Indirizzi:
INST GUSTAVE ROUSSY,DEPT MED,RUE CAMILLE DESMOULINS F-94805 VILLEJUIFFRANCE RHONE POULENC RORER F-92165 ANTONY FRANCE
Titolo Testata:
European journal of cancer
fascicolo: 7-8, volume: 31A, anno: 1995,
pagine: 1283 - 1287
SICI:
0959-8049(1995)31A:7-8<1283:C(ITTO>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT INTERFERON ALFA-2A; PHASE-II; CAMPTOTHECIN; CARCINOMA; CHEMOTHERAPY; FLUOROURACIL; MECHANISM; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Armand et al., "CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER", European journal of cancer, 31A(7-8), 1995, pp. 1283-1287

Abstract

Colorectal cancer is one of the most common cancers in the Western World. Although 50% of patients are cured by surgery alone, the outcome is poor in high-risk patients (Dukes stages B2 and C) despite adjuvantchemotherapy with 5-fluorouracil (5-FU)-based regimens. CPT-11 (irinotecan) is a promising new agent for the treatment of colorectal cancerwith a unique mechanism of action. CPT-11 is a DNA topoisomerase I inhibitor, which has not demonstrated susceptibility to the P-glycoprotein-mediated multidrug-resistant phenotype. Phase II studies with CPT-11 have demonstrated definite activity against colorectal cancer in both chemotherapy-naive and pretreated patients (response rates of 15-32%observed) even with clinical evidence of resistance to 5-FU. The response rate appears to be consistent, reproducible and equivalent to that achieved with 5-FU plus folinic acid in chemotherapy-naive patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 15:35:47